These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31435872)

  • 21. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
    Kahwaji J; Jordan SC; Najjar R; Wongsaroj P; Choi J; Peng A; Villicana R; Vo A
    Transpl Int; 2016 Dec; 29(12):1276-1285. PubMed ID: 27529314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of rituximab therapy for treatment of acute humoral rejection.
    Kaposztas Z; Podder H; Mauiyyedi S; Illoh O; Kerman R; Reyes M; Pollard V; Kahan BD
    Clin Transplant; 2009; 23(1):63-73. PubMed ID: 19200217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody-mediated rejection after kidney transplant.
    Ruangkanchanasetr P; Satirapoj B; Termmathurapoj S; Namkhanisorn K; Suaywan K; Nimkietkajorn V; Luesutthiviboon L
    Exp Clin Transplant; 2014 Aug; 12(4):328-33. PubMed ID: 25095710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of sensitized pediatric patients prior to renal transplantation.
    Pirojsakul K; Desai D; Lacelle C; Seikaly MG
    Pediatr Nephrol; 2016 Oct; 31(10):1691-8. PubMed ID: 26801944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Role of antibodies in kidney transplant].
    Ruffoni E; Seveso M; Marson P; Tison T; Cozzi E
    G Ital Nefrol; 2012; 29 Suppl 54():S54-60. PubMed ID: 22388831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody-mediated rejection after cardiac transplant: Treatment with immunoadsorption, intravenous immunoglobulin, and anti-thymocyte globulin.
    Sipahi NF; Saeed D; Makimoto H; Mehdiani A; Akhyari P; Dalyanoglu H; Reinecke P; Lichtenberg A; Boeken U
    Int J Artif Organs; 2019 Jul; 42(7):370-373. PubMed ID: 30638121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step.
    Lachmann N; Duerr M; Schönemann C; Pruß A; Budde K; Waiser J
    J Immunol Res; 2017; 2017():6872046. PubMed ID: 28255562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Desensitization Before Living Donor Kidney Transplantation in Highly HLA-Sensitized Patients: A Single-Center Study.
    De Sousa-Amorim E; Revuelta I; Blasco M; Diekmann F; Cid J; Lozano M; Sánchez-Escuredo A; Martorell J; Palou E; Campistol JM; Oppenheimer F
    Transplant Proc; 2015 Oct; 47(8):2332-5. PubMed ID: 26518919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
    Hardinger KL; Murillo D
    Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
    Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
    Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial.
    Sautenet B; Blancho G; Büchler M; Morelon E; Toupance O; Barrou B; Ducloux D; Chatelet V; Moulin B; Freguin C; Hazzan M; Lang P; Legendre C; Merville P; Mourad G; Mousson C; Pouteil-Noble C; Purgus R; Rerolle JP; Sayegh J; Westeel PF; Zaoui P; Boivin H; Le Gouge A; Lebranchu Y
    Transplantation; 2016 Feb; 100(2):391-9. PubMed ID: 26555944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Bortezomib as an Adjunctive Therapy for Refractory Chronic Active Antibody-Mediated Rejection in Kidney Transplant Patients: A Single-Center Experience.
    Larpparisuth N; Skulratanasak P; Premasathian N; Vongwiwatana A
    Transplant Proc; 2019 Dec; 51(10):3293-3296. PubMed ID: 31732214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis.
    Wan SS; Ying TD; Wyburn K; Roberts DM; Wyld M; Chadban SJ
    Transplantation; 2018 Apr; 102(4):557-568. PubMed ID: 29315141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection.
    Hong YA; Kim HG; Choi SR; Sun IO; Park HS; Chung BH; Choi BS; Park CW; Kim YS; Yang CW
    Transplant Proc; 2012 Jan; 44(1):182-4. PubMed ID: 22310610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
    Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
    Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation.
    Ibernón M; Gil-Vernet S; Carrera M; Serón D; Moreso F; Bestard O; Cruzado JM; Grinyó JM
    Transplant Proc; 2005 Nov; 37(9):3743-5. PubMed ID: 16386524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of chronic active antibody-mediated rejection in renal transplant recipients - a single center retrospective study.
    Chiu HF; Wen MC; Wu MJ; Chen CH; Yu TM; Chuang YW; Huang ST; Tsai SF; Lo YC; Ho HC; Shu KH
    BMC Nephrol; 2020 Jan; 21(1):6. PubMed ID: 31906890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteasome Inhibitor Carfilzomib-Based Therapy for Antibody-Mediated Rejection of the Pulmonary Allograft: Use and Short-Term Findings.
    Ensor CR; Yousem SA; Marrari M; Morrell MR; Mangiola M; Pilewski JM; D'Cunha J; Wisniewski SR; Venkataramanan R; Zeevi A; McDyer JF
    Am J Transplant; 2017 May; 17(5):1380-1388. PubMed ID: 28173620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib in the treatment of antibody-mediated rejection in pediatric kidney transplant recipients: A multicenter Midwest Pediatric Nephrology Consortium study.
    Kizilbash S; Claes D; Ashoor I; Chen A; Jandeska S; Matar RB; Misurac J; Sherbotie J; Twombley K; Verghese P
    Pediatr Transplant; 2017 May; 21(3):. PubMed ID: 28092129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-Center Experience of ABO-Incompatible Living-Donor Liver Transplantation With a New Simplified Intravenous Immunoglobulin Protocol: A Propensity Score-Matching Analysis.
    Kim JD; Choi DL; Kim SG; Lee AJ
    Transplant Proc; 2016 May; 48(4):1134-8. PubMed ID: 27320573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.